PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AbCellera Biologics Inc. (ABCL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA00288U1066
CUSIP00288U106
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$873.34M
EPS (TTM)-$0.51
Total Revenue (TTM)$25.73M
Gross Profit (TTM)$2.45M
EBITDA (TTM)-$146.35M
Year Range$2.65 - $7.96
Target Price$15.00
Short %8.30%
Short Ratio9.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AbCellera Biologics Inc.

Popular comparisons: ABCL vs. VOO, ABCL vs. QLD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AbCellera Biologics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%FebruaryMarchAprilMayJuneJuly
-94.96%
50.27%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

AbCellera Biologics Inc. had a return of -47.99% year-to-date (YTD) and -61.53% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-47.99%15.41%
1 month-1.66%0.33%
6 months-43.32%13.74%
1 year-61.53%21.39%
5 years (annualized)N/A13.11%
10 years (annualized)N/A10.77%

Monthly Returns

The table below presents the monthly returns of ABCL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-10.51%-1.17%-10.30%-16.56%3.70%-24.49%-47.99%
20233.95%-20.23%-10.24%-10.08%2.80%-7.32%19.66%-29.50%-15.60%-10.65%14.60%21.23%-43.63%
2022-37.13%-3.11%11.94%-21.33%-0.65%39.76%-5.73%6.37%-7.40%19.62%8.79%-21.29%-29.16%
202131.29%-28.62%-9.94%-21.53%0.68%-18.00%-31.05%10.61%19.43%-21.61%-4.77%-4.41%-64.46%
2020-31.68%-31.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABCL is 5, indicating that it is in the bottom 5% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ABCL is 55
ABCL (AbCellera Biologics Inc.)
The Sharpe Ratio Rank of ABCL is 22Sharpe Ratio Rank
The Sortino Ratio Rank of ABCL is 33Sortino Ratio Rank
The Omega Ratio Rank of ABCL is 55Omega Ratio Rank
The Calmar Ratio Rank of ABCL is 1111Calmar Ratio Rank
The Martin Ratio Rank of ABCL is 44Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ABCL
Sharpe ratio
The chart of Sharpe ratio for ABCL, currently valued at -1.14, compared to the broader market-2.00-1.000.001.002.003.00-1.14
Sortino ratio
The chart of Sortino ratio for ABCL, currently valued at -2.02, compared to the broader market-4.00-2.000.002.004.00-2.02
Omega ratio
The chart of Omega ratio for ABCL, currently valued at 0.78, compared to the broader market0.501.001.502.000.78
Calmar ratio
The chart of Calmar ratio for ABCL, currently valued at -0.66, compared to the broader market0.001.002.003.004.005.006.00-0.66
Martin ratio
The chart of Martin ratio for ABCL, currently valued at -1.48, compared to the broader market-30.00-20.00-10.000.0010.0020.00-1.48
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.82, compared to the broader market-2.00-1.000.001.002.003.001.82
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.59, compared to the broader market-4.00-2.000.002.004.002.59
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.32, compared to the broader market0.501.001.502.001.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.45, compared to the broader market0.001.002.003.004.005.006.001.45
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 6.82, compared to the broader market-30.00-20.00-10.000.0010.0020.006.82

Sharpe Ratio

The current AbCellera Biologics Inc. Sharpe ratio is -1.14. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of AbCellera Biologics Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00FebruaryMarchAprilMayJuneJuly
-1.14
1.82
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AbCellera Biologics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%FebruaryMarchAprilMayJuneJuly
-94.96%
-2.86%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AbCellera Biologics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AbCellera Biologics Inc. was 95.43%, occurring on Jul 5, 2024. The portfolio has not yet recovered.

The current AbCellera Biologics Inc. drawdown is 94.96%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.43%Dec 14, 2020894Jul 5, 2024

Volatility

Volatility Chart

The current AbCellera Biologics Inc. volatility is 21.19%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%FebruaryMarchAprilMayJuneJuly
21.19%
2.76%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AbCellera Biologics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

P/E Ratio

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for AbCellera Biologics Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items